Anthera Pharmaceuticals Inc (ANTH) is Initiated by H.C. Wainwright to Buy, Price Target at $10

Anthera Pharmaceuticals Inc (ANTH) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $10. H.C. Wainwright advised their investors in a research report released on Jul 8, 2016.

Anthera Pharmaceuticals Inc opened for trading at $3.18 and hit $3.25 on the upside on Tuesday, eventually ending the session at $3.24, with a gain of 1.89% or 0.06 points. The heightened volatility saw the trading volume jump to 2,63,848 shares. Company has a market cap of $133 M.

In a different news, on Nov 18, 2015, Colin Hislop (Chief Medical Officer) sold 12,500 shares at $5.31 per share price. According to the SEC, on Oct 13, 2015, Debra Odink (Chief Technology Officer) sold 1,205 shares at $6.15 per share price.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Company’s second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Anthera Pharmaceuticals Inc

Leave a Reply

Anthera Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Anthera Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.